Previous 10 | Next 10 |
Shares of BeiGene (NASDAQ: BGNE) and Zai Lab (NASDAQ: ZLAB) were down by 13% and 15%, respectively, as of 2:40 p.m. ET Wednesday. These two Chinese biotechs were getting crushed over fears that they might eventually be forced to delist from the Nasdaq stock exchange. Ris...
Caught up in a political battle, U.S.-listed Chinese biotechs have extended their pre-market losses into afternoon trading. Biden administration is said to be weighing stricter sanctions on China’s largest chipmaker, Semiconductor Manufacturing International Corp. (OTCQX:SMICY), and pl...
BeiGene (NASDAQ:BGNE) has completed its IPO on the STAR Market of the Shanghai Stock Exchange. BGNE shares down 6.6% premarket at $260. The RMB Shares began trading on the STAR Market on December 15, 2021, making BeiGene the first triple-listed biotechnology company on Nasdaq, the H...
BeiGene (NASDAQ:BGNE) announces that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Brukinsa (zanubrutinib) in Great Britain, for the treatment of eligible adult patients with Waldenström’s macroglobulinemia (WM)....
Authorisation is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation f...
RMB Shares begin trading on the STAR Market under the stock code “688235”, making BeiGene the first triple-listed biotech company on NASDAQ, Hong Kong Stock Exchange, and STAR Market BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driv...
BeiGene (NASDAQ: BGNE; HKEX: 06160), a global science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and Nanjing Leads Biolabs, Inc. (Leads Biolabs), a privately-owned clinical stage...
BRUKINSA demonstrated superiority in progression-free survival over chemoimmunotherapy as a first-line treatment for patients with chronic lymphocytic leukemia Consistent efficacy was observed across high-risk patient subgroups Safety results were generally consistent ...
Follow-up results from Phase 2 trial suggested intolerable adverse events leading to discontinuation of previous BTK inhibitor therapy were unlikely to recur with BRUKINSA Treatment with BRUKINSA showed continued disease control for 93.8% of trial participants, while response ...
In RATIONALE 309, tislelizumab in combination with chemotherapy significantly prolonged progression-free survival for patients, with survival benefit observed across patient subgroups The safety profile of the combination was consistent with known risks of each treatment agent...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...